Wealth Enhancement Advisory Services’s Enanta Pharmaceuticals ENTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$143K Sell
11,836
-1,479
-11% -$19.6K ﹤0.01% 3853
2026
Q2
$182K Sell
13,315
-304
-2% -$4.09K ﹤0.01% 3623
2026
Q1
$179K Buy
13,619
+2,898
+27% +$38.8K ﹤0.01% 3174
2025
Q4
$146K Buy
10,721
+74
+0.7% +$940 ﹤0.01% 3354
2025
Q3
$118K Sell
10,647
-464
-4% -$3.71K ﹤0.01% 3299
2025
Q2
$87.7K Buy
+11,111
New +$66.8K ﹤0.01% 3155

Other funds holding ENTA

Wealth Enhancement Advisory Services's ENTA Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Enanta Pharmaceuticals (ENTA) stake by 11% in Q3 2026, selling an estimated $19.6K and leaving 11,836 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #3853.

Wealth Enhancement Advisory Services first reported a position in ENTA in Q2 2025 and has held it in 6 quarters since. The position peaked at $182K in Q2 2026. 129 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

  • Wealth Enhancement Advisory Services held 11,836 shares of Enanta Pharmaceuticals worth $143K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 1,479 Enanta Pharmaceuticals shares in Q3 2026, an estimated $19.6K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3853 holding.
  • Wealth Enhancement Advisory Services first reported a position in Enanta Pharmaceuticals in Q2 2025 and has held it in 6 quarters since.
  • Wealth Enhancement Advisory Services's Enanta Pharmaceuticals position peaked at $182K in Q2 2026.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.